Sign Up to like & get
recommendations!
0
Published in 2019 at "European Journal of Pharmaceutical Sciences"
DOI: 10.1016/j.ejps.2018.10.011
Abstract: Background and objectives Vicagrel, a novel thienopyridine antiplatelet agent, is an analogue of clopidogrel in development for the treatment of acute coronary syndromes. This study investigated the pharmacokinetic properties of vicagrel after single oral dosing…
read more here.
Keywords:
healthy chinese;
clopidogrel;
vicagrel;
compared clopidogrel ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2019 at "Journal of Thrombosis and Haemostasis"
DOI: 10.1111/jth.14689
Abstract: Platelet P2Y12 antagonist ticagrelor reduces mortality after acute myocardial infarction (AMI) compared to clopidogrel, but the underlying mechanism is unknown. Because activated platelets, leukocytes, and endothelial cells release proinflammatory and prothrombotic extracellular vesicles (EVs), we…
read more here.
Keywords:
ticagrelor;
compared clopidogrel;
myocardial infarction;
acute myocardial ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2018 at "Chinese Medical Journal"
DOI: 10.4103/0366-6999.244106
Abstract: To the Editor: Current treatment guidelines for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) recommend dual antiplatelet therapy, a combination of aspirin and a P2Y12 inhibitor (i.e., clopidogrel, prasugrel, and ticagrelor)…
read more here.
Keywords:
ticagrelor;
patients acute;
compared clopidogrel;
percutaneous coronary ... See more keywords